BioCentury

8:00 AM GMT, Nov 21, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

POC for PCSK9

Regeneron Pharmaceuticals Inc. and partner Sanofi have become the first companies to report Phase II proof-of-concept data that validate blocking PCSK9 as a strategy for lowering LDL-C in patients not controlled on standard statin therapy. The companies hope to cement their first-mover status by moving into Phase III by mid-2012.

Despite the success of statins, the need for new ways to lower LDL-C has never been greater, according to Regeneron EVP and CSO George Yancopoulos. "Statins lower cholesterol by 40-50% when taken by intensive dosing regimens, but there are still millions of people not reaching their cholesterol goal who are thus left at high cardiovascular risk," he said.

Proprotein convertase subtilisin/kexin type

Read the full 1100 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.